Brainstorm Cell Therapeutics (BCLI) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BrainStorm Announces Financial Results for 2014 and Provides Business Update
March 26, 2015 8:26 AM EDTHACKENSACK, N.J. and PETACH TIKVAH, Israel, March 26, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2014.
Tony Fiorino, MD, PhD, Chief Executive Officer of BrainStorm, stated, "We are extremely pleased with the progress we made in 2014, which was very productive from a clinical as well as operational perspective.  We saw NurOwn® make significant advances in our... More
